Tailored Life Sciences Insurance
Through appointed retail and wholesale brokers, our industry specialists offer comprehensive life sciences insurance solutions globally.
The Latest in Life Science
Disappointing GLP-1 Results in Alzheimer’s Trial: Underscores Promise (and Limits) of Single-Agent Approaches
Scientists have studied Alzheimer’s disease for over a century, since Alois Alzheimer’s initial description of brain abnormalities in a patient with presenile dementia. Today, amyloid‑beta plaques and tau tangles are recognized as hallmarks of the disease, though its causes are complex and multifactorial.
PFAS in Medical & Life Sciences Products: A Regulatory & Litigation Update
In 2023, Berkley Life Sciences published a blog post titled PFAS “Forever Chemicals” in Medical and Life Sciences Products – Who Should Be Worried?. At that time, most per- and polyfluoroalkyl substances (PFAS) litigation to date focused on lawsuits against PFAS manufacturers, alleging personal injury from PFAS exposure. Since then, PFAS litigation has evolved, and both the U.S. Food and Drug Administration (FDA) and European Chemicals Agency (ECHA) have issued updates, warranting a fresh look at this topic.
Beyond Terminal: How Montana Is Redefining Right to Try Laws
Montana's Right to Try laws - Senate Bill 422 (2023) and Senate Bill 535 (2025) allow any patient, not just those with terminal illness, to access experimental treatments that have passed Phase 1 safety trials. Clinics offering these treatments must be licensed and contribute to patient support funds. Patients must provide informed consent before treatment.